Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics Inc (NTLA)
:NTLA
NTLA Analyst Ratings
Moderate Buy
15 Buy
4 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NTLA Stock 12 Month Forecast
Average Price Target
$36.06
▲(329.29% Upside)
| Highest Price Target$74.00 | Average Price Target$36.06 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
Reiterated
03/26/25
H.C. Wainwright
Initiated
03/05/25
Truist Financial
Reiterated
03/04/25
Goldman Sachs
Downgraded
02/28/25
Evercore ISI
Reiterated
02/28/25
Morgan Stanley
Reiterated
02/28/25
Barclays
Reiterated
02/28/25
JonesTrading
Reiterated
02/28/25
JMP Securities
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
Citi
$14
Hold
66.67%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NASDAQ: NTLA) and Cullinan Management (NASDAQ: CGEM)
TD Cowen
―
Buy
―
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD) and Intellia Therapeutics (NASDAQ: NTLA)
Canaccord Genuity
$74
Buy
780.95%
Upside
Reiterated
02/27/25
Intellia Therapeutics' Promising Future: Buy Rating Backed by Strong Financials and Program AdvancementsNTLA's 4Q24 earnings report was straightforward, with key programs on track. On the TTR front, mgmt continues to guide to the enrollment of at least 550 pts by YE, despite the advancement of competitive TTR products in the field. With limited updates expected from the co's MAGNITUDE and MAGNITUDE-2 trials this year, we remain focused on the longer-term Ph1 data — expected to be presented in 2025 and includes both pt types — for readthrough to the pivotal Ph3s. On the HAE side, the co newly announced the successful dosing of its first pt in its Ph3 HAELO trial, and continues to guide to completing pt enrollment in 2H25. Outside of the pipeline, NTLA gave guidance on future OpEx expectations, citing a 5-10% yoy decline in 2025, followed by a steady state to 2027 where costs associated with the clinical trials are expected to decline.
Wells Fargo
$60→$50
Buy
495.24%
Upside
Reiterated
02/27/25
Wells Fargo Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)We are adjusting our PT to $50 from $60 based on updated model assumptions. Nex-z (ATTR). For ATTR-CM, enrollment in MAGNITUDE continues to track ahead of the company's expectations, with NTLA anticipating >550 patients enrolled by YE25 and enrollment completion by 2027. For ATTRv-PN, NTLA is on track to dose the first patient in MAGNITUDE-2 in the coming weeks, with enrollment completion in 2026 and BLA filing in 2028. NTLA will also present longer-term data from the Ph1 trial for both ATTR- CM and ATTRv-PN in 2025 (cont'd inside).
BMO Capital
$50
Buy
495.24%
Upside
Reiterated
02/27/25
Intellia Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
Reiterated
03/26/25
H.C. Wainwright
Initiated
03/05/25
Truist Financial
Reiterated
03/04/25
Goldman Sachs
Downgraded
02/28/25
Evercore ISI
Reiterated
02/28/25
Morgan Stanley
Reiterated
02/28/25
Barclays
Reiterated
02/28/25
JonesTrading
Reiterated
02/28/25
JMP Securities
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
Citi
$14
Hold
66.67%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NASDAQ: NTLA) and Cullinan Management (NASDAQ: CGEM)
TD Cowen
―
Buy
―
Reiterated
02/27/25
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (NASDAQ: IRWD) and Intellia Therapeutics (NASDAQ: NTLA)
Canaccord Genuity
$74
Buy
780.95%
Upside
Reiterated
02/27/25
Intellia Therapeutics' Promising Future: Buy Rating Backed by Strong Financials and Program AdvancementsNTLA's 4Q24 earnings report was straightforward, with key programs on track. On the TTR front, mgmt continues to guide to the enrollment of at least 550 pts by YE, despite the advancement of competitive TTR products in the field. With limited updates expected from the co's MAGNITUDE and MAGNITUDE-2 trials this year, we remain focused on the longer-term Ph1 data — expected to be presented in 2025 and includes both pt types — for readthrough to the pivotal Ph3s. On the HAE side, the co newly announced the successful dosing of its first pt in its Ph3 HAELO trial, and continues to guide to completing pt enrollment in 2H25. Outside of the pipeline, NTLA gave guidance on future OpEx expectations, citing a 5-10% yoy decline in 2025, followed by a steady state to 2027 where costs associated with the clinical trials are expected to decline.
Wells Fargo
$60→$50
Buy
495.24%
Upside
Reiterated
02/27/25
Wells Fargo Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)We are adjusting our PT to $50 from $60 based on updated model assumptions. Nex-z (ATTR). For ATTR-CM, enrollment in MAGNITUDE continues to track ahead of the company's expectations, with NTLA anticipating >550 patients enrolled by YE25 and enrollment completion by 2027. For ATTRv-PN, NTLA is on track to dose the first patient in MAGNITUDE-2 in the coming weeks, with enrollment completion in 2026 and BLA filing in 2028. NTLA will also present longer-term data from the Ph1 trial for both ATTR- CM and ATTRv-PN in 2025 (cont'd inside).
BMO Capital
$50
Buy
495.24%
Upside
Reiterated
02/27/25
Intellia Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating
NTLA Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
26
36
45
41
24
Buy
7
7
7
5
3
Hold
7
9
11
11
6
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
40
52
63
58
34
Each month's total comprises the sum of three months' worth of ratings.
NTLA Financial Forecast
NTLA Stock Forecast FAQ
What is NTLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics Inc’s 12-month average price target is $36.06.
What is NTLA’s upside potential, based on the analysts’ average price target?
Intellia Therapeutics Inc has 329.29% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NTLA a Buy, Sell or Hold?
Intellia Therapeutics Inc has a consensus rating of Moderate Buy which is based on 15 buy ratings, 4 hold ratings and 1 sell ratings.
What is Intellia Therapeutics Inc’s price target?
The average price target for Intellia Therapeutics Inc is $36.06. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $74.00 ,the lowest forecast is $9.00. The average price target represents 329.29% Increase from the current price of $8.4.
The highest analyst price target is $74.00 ,the lowest forecast is $9.00. The average price target represents 329.29% Increase from the current price of $8.4.
What do analysts say about Intellia Therapeutics Inc?
Intellia Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of NTLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.